Topics / Immunology

Weekly issue

Immunology Papers of the Week

The top Immunology papers of the week: the 20 most important new papers of the past week, ranked by potential impact. A new issue comes out every Monday, covering the previous Monday-to-Sunday week.

Nov 9 - 15, 2026 · Updated

Prefer new papers every day? It's free.Daily Immunology Papers →
  1. 1
    Glycosylation of The Premembrane Protein Is Required for Dengue Virus Replication in Both C6/36 and Vero Cells

    In this manuscript, we investigated the importance of the N69 glycosylation site by generating both DENV2 and DENV4 loss-of-function viruses.

  2. 2
  3. 3
    Repurposed Endogenous Virus-like Vesicles Mediate Dendritic Cell Long-range Antigen Presentation and T Cell Activation for Enhanced Cancer Vaccination

    Here we show that dendritic cells repurpose the virus-like retrotransposon-derived Arc gene to generate endogenous virus-like vesicles (VLVs) that predominantly carry peptide-MHC and high-density co-stimulatory ligands, intensifying and extending antigen presentation.

  4. 4
  5. 5
    The Transformation of Oncology Drug Development in China: Toward A New Phase of Innovation

    We review regulatory reform and the 2015 to 2025 evolution of clinical development across small molecules, mAbs, multispecific antibodies, antibody-drug conjugates, and cell and gene therapies.

Get papers like these the day they come out, not a week later.

Follow this category
  1. 6
    Pancreatic Α Cells Function As MHC Class II-dependent Antigen-presenting Cells in Type 1 Diabetes

    Here, we show that pancreatic α cells acquire major histocompatibility complex (MHC) class II (MHC-II)-dependent antigen-presenting capacity during T1D progression.

  2. 7
    Dupilumab Modulates Type II IL-4/IL-13 Receptor-expressing Immune Cells in Eosinophilic Chronic Rhinosinusitis

    To define the cell type-specific effects of dupilumab in eCRS, we examined IL-4/IL-13 receptor-dependent transcriptional responses in tissue-resident immune cells.

  3. 8
    Mechanosensitive YAP-RUNX1 Signaling Drives T H 1 Cell Dysfunction and Tumor Immunosuppression

    Here we show that elevated tissue stiffness subverts tumor-infiltrating type 1 helper T (T 1) cells to drive immunosuppression in pancreatic cancer.

  4. 9
    Impact of Venetoclax-based Therapies on CLL-associated Autoimmune Cytopenias: A Retrospective Study Conducted By ERIC

    This study aimed to evaluate preexisting and treatment-emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax-based combinations. In this retrospective multicenter study, data from 1720 patients were collected; 23.1% received venetoclax single agent and 76.9% venetoclax combinations (mostly containing anti-CD20 monoclonal antibodies and/or BTK inhibitors).

  5. 10
    Self-amplifying RNA Vaccines Encoding Chimeric and Mosaic Hemagglutinins Confer Immunity Against Phylogenetically Diverse Influenza A Viruses

    Here, we evaluate self-amplifying mRNA (samRNA) vaccines encoding chimeric (cHA) and mosaic (mHA) hemagglutinins representing influenza A virus HA phylogenetic groups 1 and 2.

  6. 11
  7. 12
  8. 13
    Venousization Enables Angiogenesis in The Absence of VEGFR Signalling

    Here we used iFlpMosaics and iSuRe-HadCre to induce and track genetic mosaics of endothelial cells (ECs) lacking VEGFR2 during the entire embryonic and postnatal development.

  9. 14
  10. 15
    Cancer-specific T Cell Receptor Discovery Using 150,000 Clinical Genomics Samples

    Here, we identified public TCRs against therapeutically relevant targets via computational analysis of large-scale bulk RNA sequencing data obtained from routine clinical genomics testing.

  11. 16
    Reimagining COPD Treatment: Are Biologics The Next Frontier?

    Growing recognition of disease heterogeneity such as a distinct type-2/eosinophilic endotype as well as advances in biologic agents motivate reassessment of monoclonal antibodies (mAbs) as targeted treatments. This narrative review summarizes evidence from Phase 2 and 3 studies for mAbs in COPD, grouping agents by molecular targets (IL-1β, IL-4/IL-4 Rα/IL-13, IL-5/IL-5 Rα, IL-8, IL-17, IL-33/ST2/RAGE/EGFR, TSLP, TNF-α).

  12. 17
  13. 18
    Safety, Tolerability, and Efficacy of Bepranemab in People Living with Prodromal-to-mild Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial

    We aimed to investigate the safety and efficacy of bepranemab in slowing progression of tau pathology and clinical decline in people with prodromal-to-mild Alzheimer's disease.

  14. 19
    Therapeutic Landscape of Folate Receptor-α Targeting: Platforms, Progress, and Clinical Translation

    By synthesizing clinical and translational insights, this review uniquely addresses the gap by bringing together major FRα-targeted strategies within a single framework, positioning clinical trials as the organizing backbone while integrating biological and engineering insights to explain observed outcomes of FRα as both a biomarker and a therapeutic axis in oncology.

  15. 20
    Is Atherosclerosis An Autoimmune Disease?

    Additional contributors include dendritic cell-mediated antigen presentation, activation of the NLRP3 inflammasome and interleukin-1β signaling pathway, and type I interferon responses, all of which amplify vascular inflammation and plaque progression.